INDUSTRY NEWS MonoSol Rx and Midatech to Develop Insulin in PharmFilm®; To Establish Joint Venture MonoSol Rx and Midatech Group Ltd. announced their intent to form a joint venture that will focus on the development and commercialization of products combining the two companies’ respective technologies in the diabetes field. [Midatech Group Ltd. Press Release] Access Pharmaceuticals Signs Agreement with Major Global Pharmaceutical Company for Its CobOral™ Oral Insulin Formulation Access Pharmaceuticals, Inc. announced it has entered into an agreement with a major global pharmaceutical company to test Access’ oral insulin formulation based upon its proprietary vitamin B-12-based CobOral™ Drug Delivery Technology. [Access Pharmaceuticals, Inc. Press Release] Valeritas Receives FDA 510(k) Clearance for the V-Go™ Disposable Insulin Delivery Device Valeritas, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s V-Go Disposable Insulin Delivery Device for the continuous subcutaneous delivery of insulin in preset basal rates and with on-demand bolus dosing for adult patients requiring insulin. [Valeritas, Inc. Press Release] Medtronic Launches CareLink Pro 3.0, the First Diabetes Management Software to Offer Advanced Decision Support Medtronic, Inc. announced the Food and Drug Administration approval and the market launch of CareLink® Pro 3.0 Therapy Management Software, the first software program to offer advanced decision support to healthcare professionals managing diabetes. [Medtronic, Inc. Press Release] Aduro BioTech’s Clinical Results from CRS-207 Phase I Trial Presented at AACR Special Conference Aduro BioTech announced the presentation of the CRS-207 Phase I study at the AACR Special Conference on Tumor Immunology in Miami, Florida by the Principal Investigator, Dr. Dung Le of the Johns Hopkins Kimmel Cancer Center. [Business Wire] Spherix Phase II Trial with D-Tagatose Determines Minimum Dose for HbA1c and Triglycerides Spherix Incorporated announced that its Phase II diabetes clinical trial, designed to determine the minimum dose of D-tagatose capable of reducing HbA1c, found that the minimum dose capable of affecting HbA1c (7.5 g three-times daily, or TID) was within the range of doses tested (2.5, 5.0, and 7.5 g TID), with the 2.5 and 5.0 g doses producing similar responses to one another, and the 7.5 g dose producing a greater response. [Spherix Incorporated Press Release] LCT’s DIABECELL® Registered for Sale and Use in Russia Living Cell Technologies Limited announced that its Russian subsidiary, LCT Biomedical Limited, has received registration of the Company’s groundbreaking diabetes treatment, DIABECELL, as a marketable medical technology in Russia. [Living Cell Technologies Limited Press Release] EctoPharma Awarded Top SMART: SCOTLAND Grant EctoPharma announces that the Company has been awarded the maximum Feasibility Study grant of £70,000 under Scottish Enterprise’s SMART: SCOTLAND Scheme which supports innovative research and development projects within small and medium sized enterprises in Scotland. [EctoPharma Press Release] Albert Einstein College of Medicine to Study Impact of Resveratrol on Prediabetes Researchers at Albert Einstein College of Medicine of Yeshiva University have been awarded $600,000 from the American Diabetes Association to study the effect of resveratrol, a chemical compound most notably found in red wine and grapes, on impaired glucose tolerance in older adults. [Albert Einstein College of Medicine of Yeshiva University Press Release] JDRF Applauds Congress for Passage of $300 Million for Type 1 Diabetes Research and Thanks Supporters for Advocacy Efforts for Special Diabetes Program Renewal Congress passed a multi-year renewal of the Special Diabetes Program, ensuring that studies on promising diabetes treatments and avenues toward a cure continue uninterrupted. [Juvenile Diabetes Research Foundation (JDRF) International Press Release]
|
|
EVENTS (Listed by Date) Pharmacology in Stem Cells Research and Regenerative Medicine December 17, 2010 London, United Kingdom The 3rd Guangzhou International Conference on Stem Cell Biology and Regenerative Medicine December 17-19, 2010 Guangzhou, China Type 2 Diabetes, Insulin Resistance and Metabolic Dysfunction January 12-17, 2011 Dillon, United States Keystone Symposia: Obesity January 12-17, 2011 Keystone, United States 2011 Gastrointestinal Cancers Symposium January 20-22, 2011 San Francisco, United States Keystone Symposia: Epithelial Plasticity and Epithelial to Mesenchymal Transition January 21-26, 2011 Vancouver, Canada 5th Annual Stem Cells and Regenerative Medicine World Congress January 24-25, 2011 San Diego, United States Phacilitate 7th Annual Cell & Gene Therapy Forum 2011 January 24-26, 2011 Washington, D.C., United States Early Development for Innovative Diabetes & Metabolic Syndrome Therapeutics Conference January 26-27, 2011 Amsterdam, The Netherlands Joint Conference of the International Association of Pancreatology and the Indian Pancreas Club February 10-13, 2011 Maradu, India 2nd Annual International Diabetes Summit February 22-24, 2011 Dubai, United Arab Emirates World Cell Culture Congress 2011 February 28-March 2, 2011 Munich, Germany PITTCON 2011 March 13-18, 2011 Atlanta, United States United Kingdom National Stem Cell Network 2011 Annual Scientific Conference March 30-April 1, 2011 York, United Kingdom American Association for Cancer Research (AACR) 102nd Annual Meeting 2011 April 2-6, 2011 Orlando, United States World Stem Cells & Regenerative Medicine Congress 2011 May 9-11, 2011 London, United Kingdom 13th Annual C21 BioVentures May 24-26, 2011 Napa, United States Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.
JOB OPPORTUNITIES Lab Technologist – Cell Separation (STEMCELL Technologies) Lab Technologist – Human Embryonic and Induced Pluripotent Stem Cells (STEMCELL Technologies) Lab Technologist – Tissue Culture (STEMCELL Technologies) Recruit Top Talent Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News at no cost. Visit here to post your career opportunities.
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! |
| |
|